Effect of Amnion-Derived Cellular Cytokine Solution on Healing of Experimental Partial-Thickness Burns

Payne, Wyatt G.; Wachtel, Thomas L.; Smith, Charlotte A.; Uberti, M. Georgina; Ko, Francis; Robson, Martin C.
July 2010
World Journal of Surgery;Jul2010, Vol. 34 Issue 7, p1663
Academic Journal
Amnion-derived multipotent progenitor (AMP) cells, unlike most stem cells, have been demonstrated to be nontumorigenic and nonimmunogenic. Amnion-derived cellular cytokine solution (ACCS), a secreted product of AMP cells, is a cocktail of cytokines existing at physiological levels and has been used to accelerate epithelialization of experimental partial-thickness burns. Using modifications of Zawacki’s guinea pig partial-thickness scald burn model, a total of 65 animals were treated with ACCS, ACCS + AMP cells, unconditioned medium (UCM) + AMP cells, or either UCM alone or saline as controls. Dosage times ranged from every other day to once a week. Percent epithelialization was serially determined from acetate wound tracings. Histology was performed on wound biopsies. ACCS, UCM + AMP cells, and ACCS + AMP cells improved epithelialization compared with the two control groups ( P < 0.05). When ACCS was delivered more frequently, statistically significant more rapid epithelialization occurred ( P < 0.05). By day 7, all groups treated with ACCS had reached at least 90% epithelialization, whereas control groups were only 20–40% epithelialized ( P < 0.05). Histology showed excellent regeneration of the epidermis with rete ridge formation. Hair growth occurred in ACCS-treated animals but not in the control group. Amnion-derived cellular cytokine solution accelerates the healing of experimental partial-thickness burns. Based on these findings, a multicenter clinical trial is underway.


Related Articles

  • OMERACT: An international initiative to improve outcome measurement in rheumatology. Tugwell, Peter; Boers, Maarten; Brooks, Peter; Simon, Lee; Strand, Vibeke; Idzerda, Leanne // Trials;2007, Vol. 8, p38 

    OMERACT is the acronym for an international, informally organized network initiated in 1992 aimed at improving outcome measurement in rheumatology. Chaired by an executive committee, it organizes consensus conferences in a 2-yearly cycle that circles the globe. Data driven recommendations are...

  • Efficacy, Stability, and Biosafety of Sifuvirtide Gel as a Microbicide Candidate against HIV-1. Liangzhu Li; Yinyin Ben; Songhua Yuan; Shibo Jiang; Jianqing Xu; Xiaoyan Zhang // PLoS ONE;May2012, Vol. 7 Issue 5, p1 

    Sifuvirtide is a proven effective HIV-1 entry inhibitor and its safety profile has been established for systemic administration. The present study evaluated the potential of sifuvirtide formulated in a universal gel for topical use as a microbicide candidate for preventing sexual transmission of...

  • Personal Mouse Colonies Give Hope for Pancreatic Cancer Patients. Garber, Ken // JNCI: Journal of the National Cancer Institute;1/17/2007, Vol. 99 Issue 2, p105 

    The article reports on the lack of effort for the treatment of cancer patients in the U.S., despite the talk about individualized therapy. According to sources, these patients are still treated based on clinical trials of patients with general tumors instead of the particulars of their specific...

  • Which oral agent for toenail onychomycosis? Pinkowish, Mary Desmond // Patient Care;Aug2002, Vol. 36 Issue 10, p92 

    Discusses research being done on oral drug for toenail onychomycosis. Reference to study by F. Crawford et al, published in the 2002 issue of the "Archives of Dermatology"; Clinical trial conducted on the therapeutic use of terbinaline.

  • Quality of randomized clinical trials in juvenile idiopathic arthritis. L. Abrahamyan; S. R. Johnson; J. Beyene; P. S. Shah; B. M. Feldman // Rheumatology;May2008, Vol. 47 Issue 5, p640 

    Objectives. We evaluated the quality of randomized clinical trials (RCTs) of therapy for juvenile idiopathic arthritis (JIA) using an individual component approach and assessed temporal changes. Methods. A systematic review of the literature was performed to identify all RCTs involving...

  • The overall status in rheumatoid arthritis (OSRA) measure—further evidence to support its use in clinical practice. A. Hassell; P. T. Dawes; D. L. Scott; S. M. Knight; M. J. Davis; D. Mulherin // Rheumatology;May2007, Vol. 46 Issue 5, p849 

    Objectives. The overall status in rheumatoid arthritis (OSRA) instrument is a simple summary of health status, including disease activity (OSRA-A) and damage (OSRA-D) scores. Despite evidence of the validity of the OSRA, uptake has been low. This study aimed to assess the responsiveness and...

  • News Update.  // Applied Clinical Trials;Jul2002, Vol. 11 Issue 7, p22 

    Presents news items on developments in applied clinical trials in the U.S. as of July 2002. Enforcement and improvement of Food and Drug Administration's Pediatric Rule; Discontinuance of clinical development of product for treatment of moderate-to-severe psoriasis; Approval for vaccines and...

  • Business News.  // Applied Clinical Trials;Jul2002, Vol. 11 Issue 7, p67 

    Presents news items on developments in applied clinical trials as of July 2002. Newsletter on regulations, compliance and guidance activity; Research service measuring consumer purchases and use of prescription and over-the-counter medicines; Collaboration agreement to search for therapeutic...

  • Why do we need randomised controlled trials to assess... Stephenson, Judith; Imrie, John // BMJ: British Medical Journal (International Edition);02/21/98, Vol. 316 Issue 7131, p611 

    Considers the merits and limitations of randomized controlled trials in the behavioral area compared with clinical medicine. How these trials can be applied successfully to assess behavioral interventions; Merits and limitations of randomized controlled trials; Forms of randomized controlled...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics